Cox 2 Inhibitor News and Research

RSS

Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.

Green tea and COX-2 inhibitors combine to slow growth of prostate cancer

Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.

1 Mar 2007

Food can have an impact in preventing cancer

With cancer, researchers don't believe "you are what you eat"; that disease is always a direct result of what is, or what isn't, on your dinner plate.

14 Nov 2006

Doctors warned that commonly used painkillers linked to increased risk of heart attacks

Doctors in the UK are being warned that commonly used painkillers such as ibuprofen can increase the risk of heart attacks if taken over long periods.

25 Oct 2006

Latest studies reveal more risks with Vioxx

Two major studies by experts in the U.S. and Australia have provided new evidence of the cardiovascular and kidney risks attached to both COX-2 inhibitors and NSAID painkillers.

18 Sep 2006

TV advertising of prescription drugs may increase visits to doctor not actual sales

TV advertising of prescription drugs may be prompting more people to visit their doctors rather than substantially increasing sales of advertised drugs, according to research led by the Medical University of South Carolina (MUSC).

12 Sep 2006

VIOXX reduces risk of colorectal polyps

A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.

30 Aug 2006

Celebrex shown to reduce incidence of potentially pre-malignant colorectal polyps

An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex. and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal.

30 Aug 2006

COX-2 inhibitors prescribed to reduce gastrointestinal toxicity prior to the market withdrawals

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the most popular treatment for arthritis - despite their association with gastrointestinal (GI) complications, including bleeding ulcers and death.

27 Jul 2006

Experimental treatment increases response rates in advanced lung cancer

An early phase study pairing an experimental targeted therapy with a common anti-inflammatory produced promising results in patients with advanced lung cancer, researchers at UCLA's Jonsson Cancer Center reported.

1 Jun 2006

COX-1 and COX-2 enzymes may be blocked by pain medications

COX-1 and COX-2 enzymes may be blocked by pain medications such as Advil and Vioxx in a more complex manner than was previously understood, a Queen's University study has found.

29 May 2006

Drug combo significantly more effective in reducing dyspepsia in arthritis patients

UCLA/VA researchers found that for arthritis patients, taking a combination of two drugs may be most effective in protecting against stomach upset called dyspepsia, which is a side effect of common pain medications.

3 May 2006

Regular use of COX-2 inhibitors may reduce the risk of breast cancer

Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

4 Apr 2006

Immune response protects against brain tumor development

In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.

4 Apr 2006

Drugs formerly contraindicated for inflammatory bowel disease prove beneficial for pain relief

According to two studies published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease (IBD) and are not likely to cause symptom flare-ups in IBD patients in remissions

12 Feb 2006

Pfizer to fund independent trial on Celebrex and heart risks

Drug company Pfizer Inc., the maker of Celebrex, will pay for an international study of 20,000 people.

14 Dec 2005

COX-2 inhibitors may not be as safe as originally thought

There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in the British Medical Journal.

7 Dec 2005

Vaccine that targets nicotine rather than the brain's reaction to it

Since smoking became popular in America in the 1930s, lung cancer rates have continued to climb. Today, it is still the leading cause of cancer-related deaths, with totals more than the other five leading cancers combined.

3 Nov 2005

Low-dose aspirin might prevent the cardiovascular damage known to arise from use of the painkiller rofecoxib (Vioxx)

Their findings that a chemical imbalance might underlie such damage could also lead to the development of anti-inflammatory drugs without the adverse side effects, the researchers said.

20 Sep 2005

Relative of the celebrated COX-2 inhibitor celecoxib is tough tumor fighter

A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.

29 Aug 2005

Study shows how COX-2 inhibitors lead to heart disease

University of Pennsylvania School of Medicine researchers have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and stroke.

26 May 2005